Egalet Corp (EGLT) Files 10-K for the Fiscal Year Ended on December 31, 2017

Egalet Corp (EGLT, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Egalet Corp is a specialty pharmaceutical company. It is engaged in developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and in other indications. Egalet Corp has a market cap of $38.997 million; its shares were traded at around $0.85 with and P/S ratio of 0.97.

For the last quarter Egalet Corp reported a revenue of $7.80 million, compared with the revenue of $6.14 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $26.1 million, an increase of 54.1% from last year. For the last five years Egalet Corp had an average revenue decline of 0% a year.

The reported loss per diluted share was $2.05 for the year, compared with the loss per share of $15.64 in the previous year. The Egalet Corp had an operating margin of -260.94%, compared with the operating margin of -477.62% a year before. The 10-year historical median operating margin of Egalet Corp is -477.62%. The profitability rank of the company is 2 (out of 10).

At the end of the fiscal year, Egalet Corp has the cash and cash equivalents of $31.1 million, compared with $44.4 million in the previous year. The long term debt was $98.9 million, compared with $83.7 million in the previous year. Egalet Corp has a financial strength rank of 2 (out of 10).

At the current stock price of $0.85, Egalet Corp is traded at 88.7% discount to its historical median P/S valuation band of $7.52. The P/S ratio of the stock is 0.97, while the historical median P/S ratio is 8.59. The stock lost 82.28% during the past 12 months.

For the complete 20-year historical financial data of EGLT, click here.